Rozanolixizumab

Unassigned

New Medicines

Intermittent treatment of generalised myasthenia gravis (gMG) patients that have moderate to severe symptoms and are inadequately controlled on current therapy

Information

New molecular entity
UCB Pharma
UCB Pharma

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Rozanolixizumab blocks FcRn-IgG interactions so inhibiting IgG recycling & inducing removal of pathogenic IgG autoantibodies.
The incidence ranges from 0.3 to 2.8 per 100,000. It is estimated to affect more than 700,000 people worldwide. The prevalence of MG in the UK is estimated at about 15 per 100,000 population [1].
Intermittent treatment of generalised myasthenia gravis (gMG) patients that have moderate to severe symptoms and are inadequately controlled on current therapy
Subcutaneous injection